Newsmakers: PTC Therapeutics, Herbalife, Alliqua Inc, Ariad Pharmaceuticals, Alcobra Ltd Print E-mail
Monday, 06 October 2014 15:28

Global equity markets extended a rally on Monday that drew strength from a forecast-beating U.S. jobs report last week that bolstered confidence in the American economy and the Federal Reserve's monetary policy, but the dollar gave up some of its gains.

Brazil's benchmark stock index jumped more than 5 percent after a pro-business candidate surged to a strong finish in Sunday's presidential election, setting the stage for what looms as a tight runoff against leftist President Dilma Rousseff.

Investors in PTC Therapeutics, Inc.(NASDAQ:PTCT) take some money off the table today on average volume. Shares tripled from May 22's close of $15.32 to the peak of $47.20 on September 26 after Europe's CHMP issued a positive opinion favoring conditional approval of Translarna (ataluren) on May 23. The EC granted the conditional approval on August 4.

Herbalife Ltd.(NYSE:HLF) hires former FTC commissioner Pamela Jones Harbour as the newly-created head of compliance. She will lead a global team covering 91 markets. Ms. Harbour is a former prosecutor who was recently leading the privacy and data-protection team at the law firm BakerHostetler.

Alliqua Inc(NASDAQ:ALQA) amends its exclusive license agreement with Celgene subsidiary Celgene Cellular Therapies for Biovance. It now has the rights to market the advanced wound care product for podiatric and orthopedic applications.Biovance is a decellularized and dehydrated human amniotic membrane allograft which Alliqua launched in April 2014. It is indicated for the management of non-infected partial- and full-thickness wounds.

Privately-held Bellicum Pharmaceuticals pays Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) $50M for a full license to Ariad's cell-signalling technology. Under the terms of the revised agreement, Ariad will receive $15M upon the signing of the agreement, $20M by June 30, 2015 and $15M by June 30, 2016. Bellicum's license will be free of milestone and royalty payments.Bellicum is developing controllable stem cell transplant, chimeric antigen receptor T cell and

cancer vaccine product candidates for a variety of diseases.

Alcobra Ltd(NASDAQ:ADHD) tanked 53% on huge volume in response to its announcement of results from a 297-patient Phase 3 trial of Metadoxine Extended Release (MDX) in adults patients with Attention Deficit Hyperactivity Disorder (ADHD). It appears that the company excluded four undesirable responses from its Intent To Treat (ITT) population in order to achieve the desired statistical outcome.

BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and
investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus